MLP-1236 is a First in class dual inhibitor of matrix metalloproteinases (MMP) 9 and MMP 12 and has already completed Phase 1 and Phase 2a clinical studies. In preclinical models, MLP-1236 was effective in preventing/reversing the neurodegeneration associated with spinal cord injury and ischemic stroke.